Effectiveness of high‐dose i.v. immunoglobulin therapy for pregnant women with aspirin–heparin‐resistant secondary antiphospholipid syndrome

Abstract

PurposeThis study aimed to assess the efficacy of high‐dose i.v. immunoglobulin (HIVIg) therapy in pregnant women with antiphospholipid syndrome (APS) secondary to systemic lupus erythematosus with a history of pregnancy failure, despite receiving low‐dose aspirin plus unfractionated heparin therapy, of which condition being designated as “aspirin–heparin‐resistant APS” (AHRAPS).MethodsThe HIVIg therapy (20 g/d, 5 days) was performed for the pregnancies of five women with AHRAPS.ResultsFive of the eight pregnancies ended in live births. The gestational ages of delivery in four of the five pregnancies were extended, compared with previous pregnancies. The HIVIg therapy was considered to be successful for these four pregnancies. Excluding one pregnancy that ended in miscarriage with an abnormal chromosome karyotype of the villi, the HIVIg therapy was considered to be successful in four (57.1%) of the seven pregnancies of the women with AHRAPS. Although all the live newborns were prematurely delivered, no adverse effect of the HIVIg therapy was observed.ConclusionsThe HIVIg therapy might be beneficial as an immune modifier for pregnant women with AHRAPS. However, the precise indication of which women with AHRAPS who should receive HIVIg therapy remains unknown.

Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions

“…Lefkou et al demonstrated that in women with antiphospholipid syndrome and preeclampsia or intrauterine growth restriction (IUGR), the administration of 20 mg of pravastatin led to improved pregnancy outcomes and fetal health [59][60][61]. Furthermore, the efficacy of high-dose intravenous immunoglobulin therapy for pregnant women with aspirin-heparin-resistant secondary antiphospholipid syndrome was also evaluated [62]. Therapeutic options are presented in Table 3.…”